Joanna Sickler
Joanna Sickler has a total of 32 co-authors. Here are the top co-authors by number of shared publications:
- Shaowu Tang
Roche Molecular Systems, Inc., Pleasanton, California, USA
2 shared publications - Aaron Wagner
Tricore Reference Laboratories, Albuquerque, New Mexico, USA
1 shared publication - Arundhati Rao
Texas A&M College of Medicine
1 shared publication - Bianca K. Frogner
University of Washington
1 shared publication - Bradley Berg
Baylor Scott & White Health, Round Rock, TX, USA
1 shared publication - Christen Christen Griego-Fullbright
Tricore Reference Laboratory
1 shared publication
Latest Publications
- Open Access
- 8 July 2026
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 29 (1) , 1933-1941
Leveraging existing high-throughput HIV platforms for molecular Mycobacterium tuberculosis testing in Busia, Kenya: Cost and operational insights.
High costs and supply chain disruptions pose real-world challenges to the implementation of decentralized molecular platforms for Mycobacterium tuberculosis (MTB) detection in resource-limited settings. This study evaluated the cost, feasibility, and acceptability of integrating Cobas MTB and MTB-RIF/INH assays (Roche Diagnostics GmBH, Mannheim, Germany) into high-throughput HIV workflows using the Cobas 8800 system in Busia County, Kenya. Sample and testing volume data were collected from Port Victoria Hospital. Remnant sputum specimens (n = 1208) collected for testing on the decentralized GeneXpert (Cepheid, Sunnydale, CA, USA) platform (standard of care) were analyzed on the centralized Cobas 8800 system. Unit costs were estimated using an ingredients-based approach parameterized within the Testing Platform Cost Model, using real-world throughput data. Operational feasibility and technician acceptability of integrated testing on the Cobas 8800 system were assessed through qualitative surveys and workflow analysis. The integrated, high-throughput Cobas 8800 system maintained consistent testing volumes (median, 94 samples/day), whereas throughput was sporadic on decentralized GeneXpert platforms (median, four samples/day) because of supply chain disruptions and stockouts. The unit cost of the integrated approach ranged from $16.04 (best-case) to $18.97 (worst-case). The GeneXpert unit cost was $23.53 under expected utilization but $78.63 in the worst-case scenario. Operational feasibility and acceptability were high. This study was conducted in Busia county, Kenya, potentially limiting generalizability to regions with different health infrastructure or testing volumes. The analysis did not assess clinical impacts (e.g. time to treatment initiation), and assumed the availability of underutilized capacity on existing high-throughput platforms. Integrating molecular MTB testing into established high-throughput HIV workflows provided superior economic stability versus a decentralized infrastructure, and was feasible and acceptable for laboratory personnel. Strategic scaling of integrated, high-throughput diagnostics to complement near-patient testing may mitigate cost volatility, optimize underutilized testing capacity, and help bridge the national TB diagnostics gap in high-burden, resource-constrained environments.
- 8 July 2026
- Published by Taylor & Francis in Journal of Medical Economics
- Vol. 29 (1) , 1933-1941
Open AccessLeveraging existing high-throughput HIV platforms for molecular Mycobacterium tuberculosis testing in Busia, Kenya: Cost and operational insights.
High costs and supply chain disruptions pose real-world challenges to the implementation of decentralized molecular platforms for Mycobacterium tuberculosis (MTB) detection in resource-limited settings. This study evaluated the cost, feasibility, and acceptability of integrating Cobas MTB and MTB-RIF/INH assays (Roche Diagnostics GmBH, Mannheim, Germany) into high-throughput HIV workflows using the Cobas 8800 system in Busia County, Kenya. Sample and testing volume data were collected from Port Victoria Hospital. Remnant sputum specimens (n = 1208) collected for testing on the decentralized GeneXpert (Cepheid, Sunnydale, CA, USA) platform (standard of care) were analyzed on the centralized Cobas 8800 system. Unit costs were estimated using an ingredients-based approach parameterized within the Testing Platform Cost Model, using real-world throughput data. Operational feasibility and technician acceptability of integrated testing on the Cobas 8800 system were assessed through qualitative surveys and workflow analysis. The integrated, high-throughput Cobas 8800 system maintained consistent testing volumes (median, 94 samples/day), whereas throughput was sporadic on decentralized GeneXpert platforms (median, four samples/day) because of supply chain disruptions and stockouts. The unit cost of the integrated approach ranged from $16.04 (best-case) to $18.97 (worst-case). The GeneXpert unit cost was $23.53 under expected utilization but $78.63 in the worst-case scenario. Operational feasibility and acceptability were high. This study was conducted in Busia county, Kenya, potentially limiting generalizability to regions with different health infrastructure or testing volumes. The analysis did not assess clinical impacts (e.g. time to treatment initiation), and assumed the availability of underutilized capacity on existing high-throughput platforms. Integrating molecular MTB testing into established high-throughput HIV workflows provided superior economic stability versus a decentralized infrastructure, and was feasible and acceptable for laboratory personnel. Strategic scaling of integrated, high-throughput diagnostics to complement near-patient testing may mitigate cost volatility, optimize underutilized testing capacity, and help bridge the national TB diagnostics gap in high-burden, resource-constrained environments.
- Open Access
Molecular point-of-care testing for influenza A/B and respiratory syncytial virus: comparison of workflow parameters for the ID Now and cobas Liat systems
Aims: Point-of-care (POC) tests for influenza and respiratory syncytial virus (RSV) offer the potential to improve patient management and antimicrobial stewardship. Studies have focused on performance; however, no workflow assessments have been published comparing POC molecular tests. This study compared the Liat and ID Now systems workflow, to assist end-users in selecting an influenza and/or RSV POC test. Methods: Staffing, walk-away, and turnaround time (TAT) of the Liat and ID Now systems were determined using 40 nasopharyngeal samples, positive for influenza or RSV. The ID Now system requires separate tests for influenza and RSV, so parallel (two instruments) and sequential (one instrument) workflows were evaluated. Results: The ID Now ranged 4.1–6.2 minutes for staffing, 1.9–10.9 minutes for walk-away and 6.4–15.8 minutes for TAT per result. The Liat ranged 1.1–1.8 minutes for staffing, 20.0–20.5 minutes for walk-away and 21.3–22.0 minutes for TAT. Mean walk-away time comprised 38.0% (influenza positive) and 68.1% (influenza negative) of TAT for ID Now and 93.7% (influenza/RSV) for Liat. The ID Now parallel workflow resulted in medians of 5.9 minutes for staffing, 9.7 minutes for walk-away, and 15.6 minutes for TAT. Assuming prevalence of 20% influenza and 20% RSV, the ID Now sequential workflow resulted in medians of 9.4 minutes for staffing, 17.4 minutes for walk-away, and 27.1 minutes for TAT. Conclusions: The ID Now and Liat systems offer different workflow characteristics. Key considerations for implementation include value of both influenza and RSV results, clinical setting, staffing capacity, and instrument(s) placement.
Open AccessMolecular point-of-care testing for influenza A/B and respiratory syncytial virus: comparison of workflow parameters for the ID Now and cobas Liat systems
Aims: Point-of-care (POC) tests for influenza and respiratory syncytial virus (RSV) offer the potential to improve patient management and antimicrobial stewardship. Studies have focused on performance; however, no workflow assessments have been published comparing POC molecular tests. This study compared the Liat and ID Now systems workflow, to assist end-users in selecting an influenza and/or RSV POC test. Methods: Staffing, walk-away, and turnaround time (TAT) of the Liat and ID Now systems were determined using 40 nasopharyngeal samples, positive for influenza or RSV. The ID Now system requires separate tests for influenza and RSV, so parallel (two instruments) and sequential (one instrument) workflows were evaluated. Results: The ID Now ranged 4.1–6.2 minutes for staffing, 1.9–10.9 minutes for walk-away and 6.4–15.8 minutes for TAT per result. The Liat ranged 1.1–1.8 minutes for staffing, 20.0–20.5 minutes for walk-away and 21.3–22.0 minutes for TAT. Mean walk-away time comprised 38.0% (influenza positive) and 68.1% (influenza negative) of TAT for ID Now and 93.7% (influenza/RSV) for Liat. The ID Now parallel workflow resulted in medians of 5.9 minutes for staffing, 9.7 minutes for walk-away, and 15.6 minutes for TAT. Assuming prevalence of 20% influenza and 20% RSV, the ID Now sequential workflow resulted in medians of 9.4 minutes for staffing, 17.4 minutes for walk-away, and 27.1 minutes for TAT. Conclusions: The ID Now and Liat systems offer different workflow characteristics. Key considerations for implementation include value of both influenza and RSV results, clinical setting, staffing capacity, and instrument(s) placement.
- Open Access
- 26 February 2019
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 19 (1) , 1-9
Diagnosis and Management of Group a Streptococcal Pharyngitis in the United States, 2011–2015
Clinical guidelines for the diagnosis of group A streptococcal (GAS) pharyngitis recommend the use of a rapid antigen detection test (RADT) and/or bacterial culture. This study evaluated the overall diagnosis and treatment of acute pharyngitis in the United States, including predictors of test type and antibiotic prescription. A retrospective analysis of pharyngitis events from 2011 through 2015 was conducted using the MarketScan commercial/Medicare databases. A pharyngitis event was defined as occurring within 2 weeks from the index visit. Patient and provider characteristics were examined across 5 testing categories: RADT, RADT plus culture, other tests, nucleic acid amplification testing (NAAT), and no test. Multivariate models were used to identify significant predictors of NAAT use and antibiotic prescription. A total of 18.8 million acute pharyngitis events were identified in 11.6 million patients. Roughly two-thirds of events (68.2%) occurred once, and roughly a third of patients (29.1%) required additional follow-up, but hospitalization was rare (0.3%). Across all events, 43% were diagnosed by RADT, while 20% were diagnosed by RADT plus culture. The proportion of events diagnosed by NAAT increased 3.5-fold from 2011 to 2015 (0.06% vs 0.27%). Antibiotic use was frequent (49.3%), less often in combination with RADT plus culture (31.2%) or NAAT alone (34.5%) but significantly more often with RADT alone (53.4%) or no test (57.1%). Pediatricians were significantly less likely than other providers to prescribe antibiotics in their patients, regardless of patient age (p < 0.0001). Antibiotic use for sore throat remains common, with many clinicians not following current guidelines for diagnosis of GAS pharyngitis. Diagnosis of GAS pharyngitis using RADT plus culture or NAAT alone was associated with lower use of antibiotics. Diagnostic testing can help lower the incidence of inappropriate antibiotic use, and inclusion of NAAT in the clinical guidelines for GAS pharyngitis warrants consideration.
- 26 February 2019
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 19 (1) , 1-9
Open AccessDiagnosis and Management of Group a Streptococcal Pharyngitis in the United States, 2011–2015
Clinical guidelines for the diagnosis of group A streptococcal (GAS) pharyngitis recommend the use of a rapid antigen detection test (RADT) and/or bacterial culture. This study evaluated the overall diagnosis and treatment of acute pharyngitis in the United States, including predictors of test type and antibiotic prescription. A retrospective analysis of pharyngitis events from 2011 through 2015 was conducted using the MarketScan commercial/Medicare databases. A pharyngitis event was defined as occurring within 2 weeks from the index visit. Patient and provider characteristics were examined across 5 testing categories: RADT, RADT plus culture, other tests, nucleic acid amplification testing (NAAT), and no test. Multivariate models were used to identify significant predictors of NAAT use and antibiotic prescription. A total of 18.8 million acute pharyngitis events were identified in 11.6 million patients. Roughly two-thirds of events (68.2%) occurred once, and roughly a third of patients (29.1%) required additional follow-up, but hospitalization was rare (0.3%). Across all events, 43% were diagnosed by RADT, while 20% were diagnosed by RADT plus culture. The proportion of events diagnosed by NAAT increased 3.5-fold from 2011 to 2015 (0.06% vs 0.27%). Antibiotic use was frequent (49.3%), less often in combination with RADT plus culture (31.2%) or NAAT alone (34.5%) but significantly more often with RADT alone (53.4%) or no test (57.1%). Pediatricians were significantly less likely than other providers to prescribe antibiotics in their patients, regardless of patient age (p < 0.0001). Antibiotic use for sore throat remains common, with many clinicians not following current guidelines for diagnosis of GAS pharyngitis. Diagnosis of GAS pharyngitis using RADT plus culture or NAAT alone was associated with lower use of antibiotics. Diagnostic testing can help lower the incidence of inappropriate antibiotic use, and inclusion of NAAT in the clinical guidelines for GAS pharyngitis warrants consideration.
- Open Access
- 16 January 2019
- Published by Springer Nature in BMC Pediatrics
- Vol. 19 (1) , 1-8
Diagnosis and antibiotic treatment of group a streptococcal pharyngitis in children in a primary care setting: impact of point-of-care polymerase chain reaction
To compare the sensitivity and specificity of the recommended 2-step rapid antigen detection test (RADT) with confirmatory culture vs the point-of-care (POC) polymerase chain reaction (PCR) Roche cobas® Liat® Strep A test for detection of group A Streptococcus (GAS) in pediatric patients with pharyngitis, and to investigate the impact of these tests on antibiotic use in a large pediatric clinic. This prospective, open-label study was conducted at a single site during fall/winter 2016–2017. A total of 275 patients aged 3 to 18 years with symptoms of pharyngitis had a throat-swab specimen analyzed using RADT, POC PCR, and culture. The sensitivity, specificity, and percentage agreement (95% CI) between assays and a laboratory-based nucleic acid amplification test were calculated. DNA sequencing was used to adjudicate discrepancies. The RADT or POC PCR result was provided to clinicians on alternating weeks to compare the impact on antibiotic use. A total of 255 samples were evaluated; 110 (43.1%) were GAS positive. Sensitivities (95% CI) for POC PCR, RADT, and culture were 95.5% (89.7–98.5%), 85.5% (77.5–1.5%), and 71.8% (62.4–80.0%), respectively. Specificities (95% CI) for POC PCR, RADT, and culture were 99.3% (96.2–99.98%), 93.7% (88.5–97.1%), and 100% (97.5–100%), respectively. Compared with RADT, POC PCR resulted in significantly greater appropriate antibiotic use (97.1% vs 87.5%; P = .0065). Under real-world conditions, RADT results were less specific and culture results were less sensitive than found in established literature and led to increased rates of inappropriate antibiotic use. POC PCR had high sensitivity and specificity and rapid turnaround times, and led to more appropriate antibiotic use. ID number ISRCTN84562679 . Registered October 162,018, retrospectively registered.
- 16 January 2019
- Published by Springer Nature in BMC Pediatrics
- Vol. 19 (1) , 1-8
Open AccessDiagnosis and antibiotic treatment of group a streptococcal pharyngitis in children in a primary care setting: impact of point-of-care polymerase chain reaction
To compare the sensitivity and specificity of the recommended 2-step rapid antigen detection test (RADT) with confirmatory culture vs the point-of-care (POC) polymerase chain reaction (PCR) Roche cobas® Liat® Strep A test for detection of group A Streptococcus (GAS) in pediatric patients with pharyngitis, and to investigate the impact of these tests on antibiotic use in a large pediatric clinic. This prospective, open-label study was conducted at a single site during fall/winter 2016–2017. A total of 275 patients aged 3 to 18 years with symptoms of pharyngitis had a throat-swab specimen analyzed using RADT, POC PCR, and culture. The sensitivity, specificity, and percentage agreement (95% CI) between assays and a laboratory-based nucleic acid amplification test were calculated. DNA sequencing was used to adjudicate discrepancies. The RADT or POC PCR result was provided to clinicians on alternating weeks to compare the impact on antibiotic use. A total of 255 samples were evaluated; 110 (43.1%) were GAS positive. Sensitivities (95% CI) for POC PCR, RADT, and culture were 95.5% (89.7–98.5%), 85.5% (77.5–1.5%), and 71.8% (62.4–80.0%), respectively. Specificities (95% CI) for POC PCR, RADT, and culture were 99.3% (96.2–99.98%), 93.7% (88.5–97.1%), and 100% (97.5–100%), respectively. Compared with RADT, POC PCR resulted in significantly greater appropriate antibiotic use (97.1% vs 87.5%; P = .0065). Under real-world conditions, RADT results were less specific and culture results were less sensitive than found in established literature and led to increased rates of inappropriate antibiotic use. POC PCR had high sensitivity and specificity and rapid turnaround times, and led to more appropriate antibiotic use. ID number ISRCTN84562679 . Registered October 162,018, retrospectively registered.
- Open Access
- 16 October 2018
- Published by Springer Nature
Comparing tests for Group A Streptococcus bacteria in children with throat infections
- 16 October 2018
- Published by Springer Nature
Open AccessComparing tests for Group A Streptococcus bacteria in children with throat infections
- 22 December 2016
- Published by SAGE Publications in Clinical Pediatrics
- Vol. 56 (12) , 1128-1134
Accurate Detection of Streptococcus pyogenes at the Point of Care Using the cobas Liat Strep A Nucleic Acid Test
The performance of a polymerase chain reaction–based point-of-care assay, the cobas Strep A Nucleic Acid Test for use on the cobas Liat System (cobas Liat Strep A assay), for the detection of group A Streptococcus bacteria was evaluated in primary care settings. Throat swab specimens from 427 patients were tested with the cobas Liat Strep A assay and a rapid antigen detection test (RADT) by existing medical staff at 5 primary care clinics, and results were compared with bacterial culture. The cobas Liat Strep A assay demonstrated equivalent sensitivity (97.7%) and specificity (93.3%) to reference culture with a 15-minute turnaround time. In comparison to RADTs, the cobas Liat Strep A assay showed improved sensitivity (97.7% Liat vs 84.5% RADT). The Clinical Laboratory Improvement Amendments–waived cobas Liat Strep A assay demonstrated the ease of use and improved turnaround time of RADTs along with the sensitivity of culture.
- 22 December 2016
- Published by SAGE Publications in Clinical Pediatrics
- Vol. 56 (12) , 1128-1134
Accurate Detection of Streptococcus pyogenes at the Point of Care Using the cobas Liat Strep A Nucleic Acid Test
The performance of a polymerase chain reaction–based point-of-care assay, the cobas Strep A Nucleic Acid Test for use on the cobas Liat System (cobas Liat Strep A assay), for the detection of group A Streptococcus bacteria was evaluated in primary care settings. Throat swab specimens from 427 patients were tested with the cobas Liat Strep A assay and a rapid antigen detection test (RADT) by existing medical staff at 5 primary care clinics, and results were compared with bacterial culture. The cobas Liat Strep A assay demonstrated equivalent sensitivity (97.7%) and specificity (93.3%) to reference culture with a 15-minute turnaround time. In comparison to RADTs, the cobas Liat Strep A assay showed improved sensitivity (97.7% Liat vs 84.5% RADT). The Clinical Laboratory Improvement Amendments–waived cobas Liat Strep A assay demonstrated the ease of use and improved turnaround time of RADTs along with the sensitivity of culture.